Norgine France with 100 years of expertise celebrates new manufacturing investment

CORPORATE MEDIA RELEASE

NORGINE FRANCE WITH 100 YEARS OF EXPERTISE CELEBRATES NEW MANUFACTURING INVESTMENT

AMSTERDAM, The Netherlands, 11 June 2018, 12:00 BST / 13:00 CET. Norgine B.V. a European specialist pharmaceutical company announced today the visit of Olivier Marleix, Member of the French Assemblée Nationale Eure-et-Loir, Wassim Kamel, Sub-Prefect of Dreux and Gérard Hamel, Mayor of Dreux to celebrate investment at its manufacturing site in Dreux, France.

Since 2015, the company has invested a total of EUR 8 million in its manufacturing and quality capabilities at the Dreux facility. This includes new technology to produce MOVICOL^® Ready to Take and additional packaging facilities for LYMPHOSEEK^® and DANTRIUM^® IV.

Norgine employs over 1,000 personnel in Europe and Australia – with over 200 employees in France, located in Dreux and Rueil Malmaison:

• Dreux site: manufacturing, quality control and contract manufacturing activities. Norgine produces around 15 medicinal products in Dreux to supply 50 countries.
• Rueil Malmaison: commercial activities.

Peter Stein, CEO at Norgine said: “Part of Norgine’s strength as a partner lies in its high quality manufacturing and distribution facilities in Hengoed, Wales and Dreux, France. These help to enable Norgine to integrate and launch new innovative products which deliver value to healthcare professionals and improve patients’ lives.”

Norgine, Dreux site            

Peter Stein, CEO at Norgine 

M. Olivier Marleix, Député Eure-et-Loir 

M. Wassim Kamel, Sous-Préfet de Dreux

M. Gérard Hamel, Maire de Dreux

Notes to Editors:

MOVICOL^® Ready to Take (Macrogol 3350, Sodium Hydrogen Carbonate, Sodium Carbonate, Potassium Chloride) is a treatment for  constipation and faecal impaction in adults and adolescents (12 years and above). MOVICOL^® Ready to Take is a ready mixed, pocket size dose that can be easily incorporated into daily life. 

LYMPHOSEEK^® (technetium Tc 99m tilmanocept) is a radiopharmaceutical used for diagnostic purposes by nuclear medicine specialists and surgeons. It is specifically designed for a procedure called sentinel lymph node biopsy (SLNB) and represents a significant alternative to the current method of identifying sentinel lymph nodes in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. Norgine in-licensed LYMPHOSEEK^® from Navidea Biopharmaceuticals Inc for the commercialisation and distribution in Europe and certain other key markets. 

DANTRIUM^® IV is an injectable product to treat a life-threatening condition, malignant hyperthermia (a rapid rise in body temperature) which causes muscle stiffness and spasms and can occur during and after surgery with certain types of anesthesia.

About Norgine

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.

Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.

Norgine specialises in gastroenterology, hepatology, cancer and supportive care.

Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

MOVICOL and DANTRIUM are trademarks of the Norgine group of companies.

Media Contact:

Isabelle Jouin, T: +44 (0)1895 826237

Follow us @norgine

https://www.linkedin.com/company/norgine/